Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | KAT2B | Q92831 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | POLA1 | P09884 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2527082 | 1.00 | TSHR (0.64) | TSHRALDH1A1LMNATP53KAT2B | |
| SCHEMBL7407458 | 1.00 | TSHR (0.64) | TSHRALDH1A1LMNATP53KAT2B | |
| SCHEMBL19141 | 1.00 | TSHR (0.64) | TSHRALDH1A1LMNATP53KAT2B | |
| SCHEMBL4204017 | 1.00 | TSHR (0.64) | TSHRALDH1A1LMNATP53KAT2B | |
| SCHEMBL7408161 | 1.00 | TSHR (0.64) | TSHRALDH1A1LMNATP53KAT2B | |
| SCHEMBL989611 | 1.00 | TSHR (0.64) | TSHRALDH1A1LMNATP53KAT2B | |
| SCHEMBL9353850 | 1.00 | TSHR (0.64) | TSHRALDH1A1LMNATP53KAT2B | |
| SCHEMBL642929 | 0.98 | TSHR (0.67) | TSHRALDH1A1LMNATP53KAT2B | |
| SCHEMBL48697 | 0.93 | TSHR (0.75) | TSHRALDH1A1LMNATP53KAT2B | |
| SCHEMBL3502791 | 0.87 | TSHR (0.82) | TSHRALDH1A1LMNAKMT2ARECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053188-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF HYDROXAMIC ACID DERIVATIVES | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE(TGEN (US) | 2012-03-01 | — | — | US | claimed |
| WO-2009100045-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF HYDROXAMIC ACID DERIVATIVES | TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2009-08-13 | — | — | WO | claimed |
| CN-122055150-A | Cyproheptadine derivatives | 思凯生科股份有限公司 | 2026-05-15 | — | — | CN | disclosed |
| US-9381196-B2 | Compounds, pharmaceutical compositions and methods of use of hydroxamic acid derivatives | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150196559-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF HYDROXAMIC ACID DERIVATIVES | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2015-07-16 | — | — | US | disclosed |
| US-8987468-B2 | Compounds, pharmaceutical compositions and methods of use of hydroxamic acid derivatives | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2015-03-24 | — | — | US | disclosed |
| US-20120053188-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF HYDROXAMIC ACID DERIVATIVES | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE(TGEN (US) | 2012-03-01 | — | — | US | disclosed |
| WO-2009114470-A2 | TETRAHYDROINDOLE AND TETRAHDYROINDAZOLE AS HSP90 INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2009-09-17 | — | — | WO | disclosed |
| WO-2009100045-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF HYDROXAMIC ACID DERIVATIVES | TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20080262011-A1 | Modulator | UCL BIOMEDICA PLC (GB) | 2008-10-23 | — | — | US | disclosed |
| US-20080262011-A1 | Modulator | UCL BIOMEDICA PLC (GB) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053188-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF HYDROXAMIC ACID DERIVATIVES | HDAC5, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HDAC4 | TSHR 3959/4885ALDH1A1 863/4885LMNA 1006/4885 |
| US-20080262011-A1 | Modulator | CHRNA10, CNR1, CHRNA9 | TSHR 68/4885ALDH1A1 3671/4885LMNA 3976/4885 |
| US-20150196559-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF HYDROXAMIC ACID DERIVATIVES | HDAC5, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HDAC4 | TSHR 3959/4885ALDH1A1 863/4885LMNA 1006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.